Thalidomide therapy for low-risk Myelodysplasia☆
To access this article, please choose from the options below
☆ On behalf of the UK MDS Forum.
PII: S0145-2126(04)00231-0
doi:10.1016/j.leukres.2004.05.017
© 2004 Elsevier Ltd. All rights reserved.
☆ On behalf of the UK MDS Forum.
PII: S0145-2126(04)00231-0
doi:10.1016/j.leukres.2004.05.017
© 2004 Elsevier Ltd. All rights reserved.